Search clinical trials for: Placebo (NNC0480-0389)

Total 53531 results

Novo Nordisk A/S

Completed

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan, Hungary, Poland, Russian Federation, Bulgaria, Serbia, Greece, Denmark
Novo Nordisk A/S

Completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Healthy Volunteers Type 2 Diabetes

Japan
Novo Nordisk A/S

Completed

First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men

Diabetes Mellitus, Type 2

China
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

Obesity

United States
Novo Nordisk A/S

Recruiting

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Obesity

Japan
Novo Nordisk A/S

Completed

A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Recruiting

A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.

Healthy Volunteers - Liver Diseases

United Kingdom
Novo Nordisk A/S

Completed

A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels

Healthy Volunteers | Hypercholesterolaemia

United Kingdom
Novo Nordisk A/S

Recruiting

A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

Healthy Volunteers

Austria
Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men

Healthy Volunteers | Atherosclerotic Cardiovascular Disease

Japan
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
Novo Nordisk A/S

Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Poland, Hungary
Novo Nordisk A/S

Recruiting

A Research Study of a New Medicine (NNC0650-0013) in Healthy Men

Healthy Participants

Germany
AbbVie (prior sponsor, Abbott)

Completed

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

Healthy Volunteers; High Cholesterol

United States
Novo Nordisk A/S

Withdrawn

Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers

Obesity | Metabolism and Nutrition Disorder
Novo Nordisk A/S

Recruiting

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

Healthy Volunteers

United Kingdom
Affibody
Parexel

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039

Healthy Volunteers

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump

Diabetes Mellitus, Type 1

Austria
Chr Hansen

Completed

Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population

Inflammation

Ireland
Novo Nordisk A/S

Completed

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Atherosclerotic Cardiovascular Disease

Germany, Poland, United States, Netherlands, Japan, Greece, Belgium
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Type 2 Diabetes | Healthy Volunteers | High Blood Cholesterol Levels

Germany, Canada
Biocad

Completed

The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis (AURORA)

Seropositive RA

Russian Federation, Belarus
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd

Recruiting

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Australia
Novo Nordisk A/S

Completed

A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants

Healthy Volunteers | Elevated Cholesterol | Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk

Germany
Genentech, Inc.

Completed

Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Tumor

Canada, United States
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Diabetes Mellitus, Type 2

Germany
Abbott

Terminated

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
University of Pennsylvania

Terminated

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

Nicotine Addiction

United States
Novo Nordisk A/S

Terminated

A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function

Chronic Kidney Disease

Germany
Abbott

Terminated

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Shandong Luoxin Pharmaceutical Group Stock Co.,...

Completed

A Phase I Study of LX-039 Tablets

Advanced Breast Cancer

China
National Center of Neurology and Psychiatry, Japan
Nippon Shinyaku Co., Ltd.

Completed

Exploratory Study of NS-089/NCNP-02 in DMD

Duchenne Muscular Dystrophy

Japan
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Non-Hodgkin Lymphoma | NK/T Cell Lymphoma | Vascular Immunomother T Cell Lymphoma

China
AbbVie (prior sponsor, Abbott)

Completed

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Sun Pharma Advanced Research Company Limited

Completed

Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer

Breast Cancer and Ovarian Cancer
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Solid Tumor | Recurrent Glioma

China
Australian Catholic University
Curtin University; Pendulum Therapeutics

Active, not recruiting

OsteoPreP: Food Supplements for Postmenopausal Bone Health (OsteoPreP)

Glucose Metabolism Disorders | Postmenopausal Osteopenia | Age-related Cognitive Decline | Age-Related Sarcopenia | Bone Loss, Age Related

Australia

3

Subscribe